Thursday, May 17, 2018

Cambrex Reports Expansions at its High Point, NC Facility

On May 15, 2018, Cambrex reported that it had completed a pilot plant expansion at its High Point, NC facility with the installation and commissioning of a fourth reactor suite. The new 400-sq.-ft. suite includes two 2000 L glass-lined reactors and a Hastelloy C22 filter dryer, allowing the manufacture of batch sizes ranging from 10–100kg under cGMP conditions for clinical-phase projects. The installation increased the site’s reactor capacity by approximately 30%, according to a company press release.

The company noted that it also upgraded its analytical chromatography data systems for quality control and analytical R&D to Empower 3 software (Waters).

In April 2018, the company announced it completed installation of multiple continuous flow reactor platforms at the High Point facility; the platforms will focus on the rapid development of processes to supply clinical and commercial demand for chemical syntheses.

The company also completed the construction and validation of a $3.2-million, 11,000-sq.-ft. analytical laboratory at the High Point facility to meet customer demand for analytical development and validation services in support of clinical stage cGMP products. More than 20 analytical instruments, including high-performance liquid chromatography (HPLC), mass spectrometers, and support equipment were added, and 12 analytical scientists will be hired, the company reports.

The company also reported on May 15 progress in construction for a $24-million facility at the company’s Charles City, IA plant, for the manufacture of highly potent APIs. A 4500-sq.-ft. production area, which will have a reactor capacity of 2200 gallons and will manufacture batches from 50­–300kg, will operate to an occupational exposure limit down to 0.1µg/m³.

The existing small-scale manufacturing area will be reconfigured, providing a single high-containment building to support early stage development and manufacturing. The facility is expected to be operational in the first half of 2019, the company reports.

Source: Cambrex Corporation

 

Source link

Wednesday, May 16, 2018

Irish engineering group wins major contract in Sweden

Irish engineering and construction management firm DPS has won a major contract from the global pharmaceutical company AstraZeneca.

DPS, which employs over 1,300 people, is to provide engineering, procurement, construction management and validation (EPCMV) services for small and medium sized projects on AstraZeneca’s pharmaceutical site in Södertälje, Sweden.

The contract win means that DPS will now establish a new office in Sweden to service AstraZeneca initially, as well as other clients in the Nordic region at a later stage.

The value of the contract has not been disclosed, but it is expected that over 100 DPS engineering personnel potentially will be working on AstraZeneca projects, depending on capital expenditure levels.

Frank Keogh said: “DPS is delighted to have won this contract and we are confident the combination of a substantial local office and local partners in Sweden, as well as our large pharma centre of excellence offices in Dublin and Cork will ensure a quality and cost effective delivery model for AstraZeneca. As with all our clients we will work with AstraZeneca in a true partnership, building a long term relationship”.

DPS operates in Ireland, Netherlands, Belgium, Sweden, Israel, Singapore and the United States.

Source link

Tuesday, May 15, 2018

2 Day Course: FDA Trends for Computer System Validation (CSV) Compliance and Enforcement (Boston, MA – June 25-26, 2018) – ResearchAndMarkets.com | Technology

This seminar will focus on the key areas that are most important, including security and data integrity. Implementing and following the System Development Life Cycle (SDLC) methodology is the best approach for Computer System Validation and maintaining data integrity. The life cycle approach takes all aspects of validation into account throughout the life of the system and the data that it houses. The data is a key asset for any FDA-regulated company and must be protected through its entire retention period.

This session will provide some insight into current trends in compliance and enforcement. Some are based on technology changes, and these will continue to have an impact as new innovations come into use in the industry.

Areas Covered in the Session

Computer System Validation (CSV)System Development Life Cycle (SDLC) Methodology”GxP” – Good Manufacturing, Laboratory and Clinical Practices21 CFR Part 11, Electronic Records/Electronic Signatures (ER/ES)Data Archival to ensure security, integrity and complianceValidation Strategy that will take into account the system risk assessment and system categorization (GAMP V) processesPolicies and ProceduresCritical TrainingRecent FDA findings for companies in regulated industriesRecent trends in technology that need to be addressed in the CSV approachQ&A

Laura Wood, Senior Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Pharmaceutical Manufacturing

KEYWORD: UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT HEALTH PHARMACEUTICAL FDA

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 05/15/2018 07:19 AM/DISC: 05/15/2018 07:19 AM

Copyright Business Wire 2018.



Source link

DPS Group Wins Contract in Sweden from AstraZeneca

As a result of winning this contract, DPS Group is now establishing an office in Sweden, which will be used initially to service AstraZeneca exclusively but later to service other clients in Sweden.  

DPS Group CEO Frank Keogh said: “DPS are delighted to have won this contract and we are confident the combination of a substantial local office and local partners in Sweden, as well as our large pharma centre of excellence offices in Dublin and Cork will ensure a quality and cost effective delivery model for AstraZeneca. As with all our clients we will work with AstraZeneca in a true partnership, building a long term relationship.”

The value of the contract has not been disclosed but it is expected that over 100 DPS engineering personnel potentially will be working on AstraZeneca projects depending on capital expenditure levels.

About DPS Group
DPS Group is a global engineering, consulting and project management company, serving high-tech industries around the world. DPS delivers services for clients across the complete engineering and construction value chain including feasibility studies, concepts, consulting, architecture, engineering, professional outsourcing, procurement, construction management, commissioning, qualification and validation; as well as contingent staffing solutions.

DPS applies its extensive Process Engineering expertise built over 40+years, as well as significant Lean Construction experience to assist our clients in high-end process sectors such as pharmaceuticals, biotech, medical devices and semiconductors. DPS deliver their manufacturing facilities speedily, safely and cost effectively. What sets us apart are the partnerships we build with our clients through a fundamental understanding of their businesses and our own agility, flexibility, original thinking and our high-calibre people.

We have grown substantially in recent years and now employ over 1,300 people in our offices and on client sites in Ireland, Netherlands, Belgium, Sweden, Israel, Singapore, Switzerland, the United Kingdom and the United States. For more information, visit https://ift.tt/2dvSn1u.

Contact: Annette O’Hara, Group Marketing Manager  
O +353-1-466-1755
M +353-87-248-2573
E annette.ohara@dpsgroupglobal.com

SOURCE DPS Group



Source link

AstraZeneca (AZN) Partnered with DPS Group in Sweden for Construction Contract

The UK researched-based biopharmaceutical company, AstraZeneca PLC (NYSE:AZN) partnered with DPS Group, the global and European based engineering, consulting and project management company, in a construction contract.

The contract is specific for AstraZeneca’s pharmaceutical site in Swedan.

The terms and condition of contract was not disclosed by both companies even the value, however, DPs Group said that it will provide Engineering, Procurement, Construction Management and Validation (EPCMV) services for all small and medium projects of AstraZeneca’s site in Swedan.

DPS Group serving to their clients with lean construction experience in pharmaceuticals, biotech, medical devices and semiconductors from over 40 years in US and Europe. With over 1,300 employees, the construction firm presently serving their customers in Ireland, Netherlands, Belgium, Sweden, Israel, Singapore, Switzerland, the United Kingdom and the United States.

After winning the construction contract from AstraZeneca’s, DPS Group said that it is now building its office in Swedan completely for AstraZeneca which will provide services to AstraZeneca on starting and later on for other clients.

“DPS are delighted to have won this contract and we are confident the combination of a substantial local office and local partners in Sweden, as well as our large pharma center of excellence offices in Dublin and Cork will ensure a quality and cost-effective delivery model for AstraZeneca. As with all our clients we will work with AstraZeneca in a true partnership, building a long-term relationship.” CEO of DPS Group, Frank Keogh, commented on the winning contract from AsrtaZeneca (AZN).

However, in other news for AstraZeneca, the biotech firm said that it will published its financial results for the first quarter of 2018 on Friday, May 18, 2018 on its website at 07:00 UK time.

A webcast for the financial results also will take place at 12:00 UK time on Friday, May 18, 2018.

With the $90.69 market value, AstraZeneca PLC (NYSE:AZN)’s shares up 0.05% or $0.02 cents to close the Monday trading session at $36.42. The biotech company posted EPS of $1.18 for the trailing twelve months.

Source link

AstraZeneca (AZN) Partnered with DPS Group in Sweden for Construction Contract

The UK researched-based biopharmaceutical company, AstraZeneca PLC (NYSE:AZN) partnered with DPS Group, the global and European based engineering, consulting and project management company, in a construction contract.

The contract is specific for AstraZeneca’s pharmaceutical site in Swedan.

The terms and condition of contract was not disclosed by both companies even the value, however, DPs Group said that it will provide Engineering, Procurement, Construction Management and Validation (EPCMV) services for all small and medium projects of AstraZeneca’s site in Swedan.

DPS Group serving to their clients with lean construction experience in pharmaceuticals, biotech, medical devices and semiconductors from over 40 years in US and Europe. With over 1,300 employees, the construction firm presently serving their customers in Ireland, Netherlands, Belgium, Sweden, Israel, Singapore, Switzerland, the United Kingdom and the United States.

After winning the construction contract from AstraZeneca’s, DPS Group said that it is now building its office in Swedan completely for AstraZeneca which will provide services to AstraZeneca on starting and later on for other clients.

“DPS are delighted to have won this contract and we are confident the combination of a substantial local office and local partners in Sweden, as well as our large pharma center of excellence offices in Dublin and Cork will ensure a quality and cost-effective delivery model for AstraZeneca. As with all our clients we will work with AstraZeneca in a true partnership, building a long-term relationship.” CEO of DPS Group, Frank Keogh, commented on the winning contract from AsrtaZeneca (AZN).

However, in other news for AstraZeneca, the biotech firm said that it will published its financial results for the first quarter of 2018 on Friday, May 18, 2018 on its website at 07:00 UK time.

A webcast for the financial results also will take place at 12:00 UK time on Friday, May 18, 2018.

With the $90.69 market value, AstraZeneca PLC (NYSE:AZN)’s shares up 0.05% or $0.02 cents to close the Monday trading session at $36.42. The biotech company posted EPS of $1.18 for the trailing twelve months.

Source link

CGMP Violations Found at India Facility

FDA sent a warning letter to Goran Pharma Private Limited citing inadequate quality control violations.

FDA sent a warning letter, dated April 24, 2018, to Goran Pharma Private Limited after an inspection of the company’s Sihor, Gujarat, India facility found deviations from current good manufacturing practices (CGMPs). A variety of violations found during the inspection included failure to identify ingredients from suppliers, inadequate quality control, and inappropriate equipment use. The inspection was conducted by FDA from Nov. 13–15, 2017.

Specifically, FDA stated in the warning letter that the company failed to test components from suppliers to “determine their conformance to identity, purity, strength, and other appropriate specifications. Your firm released components for use in drug product manufacturing based on certificates of analysis (COA) from your supplier without establishing the reliability of the suppliers’ analyses through appropriate validation.”

The agency requested the company provide a detailed description of how it plans on ensuring that components used in manufacturing be withheld from use until they have been tested. The company must also show how it will quality suppliers’ COAs, perform detailed risk assessments, and do a comprehensive review of laboratory practices, methods, equipment, and analyst competencies.

The warning letter also indicated that the company’s response to inspectors finding that inappropriate systems were used was lacking. The agency requested the company provide a detailed validation plan for its new system, procedures for routine monitoring of the system, a risk assessment of product manufactured on the old system, and reasons for why the company relied on past data to characterize the system’s state of control.

Inadequate control of air pressure, micro-organisms, dust, humidity, and temperature was also observed by inspectors. The agency requested the company provide an action plan for ensuring control and monitoring of temperature, humidity, and air cleanliness as well as an independent assessment of the company’s facilities and equipment.

The warning letter stated that FDA had placed the firm on Import Alert 66-40 on March 5, 2018.

FDA recommended the company hire a third-party CGMP consultant to audit the company’s operations.

Source: FDA

 

Source link

Monday, May 14, 2018

Calibration And Validation Of A Headspace Gas Chromatographic Method – Covering the Printing Inks, Coatings and Allied Industries

Pallavi Gupta, Ruchi Gupta, Pinaki Ranjan Samanta and Pradeep Shah, Uflex Ltd (Chemical Division), Noida, India05.11.18

A simple and sensitive method for the simultaneous determination of methanol, ethanol, iso propyl alcohol(IPA), methyl ethyl ketone (MEK), methyl isobutyl ketone (MIBK), n-propyl alcohol (n-PA), ethyl acetate (EA), n-butanol, n-propyl acetate (n-PAc), toluene and ortho-xylene by headspace techniques with FID detection is described. An efficient and sensitive method was successfully developed and validated for the determination of above mentioned solvents of varying polarity used as residual solvents from printing ink.

Based on Good Manufacturing Practices, measuring residual solvents is mandatory for the release testing of all active chemical ingredients. The method was validated for repeatability, linearity, limit of detection, limit of quantification and recovery according to the International Conference on Harmonization guidelines. The method validation results indicate that the method is accurate, precise, linear and sensitive for solvents assessed in the printing ink. Excellent results were obtained, within the globally accepted validation reference values, particularly taking into account the low concentration levels investigated.

Key Words: Validation, residual solvents, GC-HS, printing ink, volatiles.

* Corresponding Author: pallavi.gupta24192gmail.com

Abbreviations: Iso propyl alcohol (IPA), methyl ethyl ketone (MEK), methyl isobutyl ketone (MIBK), n-propyl alcohol (n-PA), ethyl acetate (EA), n-butanol, n-propyl acetate (n-PAc),ortho-xylene (xylene).

Residual solvents or organic volatile impurities are a potential toxic risk of pharmaceutical [1] or any other food-related products, whether it is packaging laminates of food as itself, and have been a concern of manufacturers for many years. Moreover, residual solvents can also affect the quality and stability of not only drug substances [2] but also packaging laminates of food as itself.

Thus, acceptable levels of many solvents are included in regulatory guidance documents, in particular in guideline Q3C issued by the International Conference on Harmonization of technical requirements for registration of pharmaceuticals for human use (ICH)[3].

The technique of static headspace gas chromatography has great acceptance in the chemical industry, especially for determination of solvents in printing inks and laminating films. Most chemical industries in the world have this equipment and perform this analysis on a routine basis, but in many of these laboratories, the equipment is exclusively employed to determine solvents, even when this technique can be used to determine many other substances of toxicological interest, such as volatile substances, without major changes to the equipment. We can conclude that these laboratories do not exploit all the possibilities of the technique.

Determination of residual solvents using GC with a flame ionization detector (FID) is the most common technique in the pharmaceutical industry as well as the chemical industry because of its high separation efficiency and sensitivity for volatile organic compounds. The headspace gas chromatography (HS-GC) method has been used for the determination of residual solvents in pharmaceutical compounds [4,5] and also packaging laminates of food.

The determination of volatile substances is one of the most important tests in chemical toxicology. Volatile substances can be defined as those organic compounds whose vapor pressures are greater than or equal to 0.1 mm Hg at 20°C. The determination of volatile substances in polymeric samples has been carried out through titrations, spectrophotometric methods and chromatographic methods. Titrations and spectrophotometric methods are not specific and usually lack sufficient sensitivity, besides not being able to analyze simultaneously all the volatile substances.

In contrast, gas chromatography is qualitative (by the use of retention time) and quantitative (by the use of signal strength), so it is able to analyze simultaneously several volatile substances with the adequate sensitivity and specificity necessary in chemical environments.

The authors have tried to validate a method by using gas chromatography to analyze volatile (%) and residual volatiles. This paper demonstrates a thorough study to establish a validated method for analysis involving volatiles quantitatively and qualitatively.

All gas chromatography experiments were conducted with Perkin Elmer Clarus 500, Headspace Turbo matrix 16 Auto-samplers.

The chromatographic oven temperature program was as follows: the initial temperature of 40°C was held for 8 minutes, 15°C/min to 100°C and 25°C/min up to 250°C and FID Detector temperature set at 260°C. Column used Elite-5 (Cross bond 5% diphenyl-95% dimethyl polysiloxane) length 30 meter, diameter 0.25mm ID, thickness 0.25 micrometer. Nitrogen as carrier gas with 22.8 cm/sec, flow rate of hydrogen was 40ml/min, Air was 400ml/min and sample flow rate was 1ml/min.

Headspace conditions of the oven temperature were set at 90°C and Needle temperatures were 100°C. The pressurization time was 1 min and the Transfer line temperature was 110°C.

A. Material GC-HS analysis was carried out by using analytical grade (AR) solvent with purity of more than 99% such as methanol (99.5%), ethanol (97.5%), IPA (99.7%), n-propyl alcohol (99.7%), MEK (99.5%), EA (99%), n-butanol (99.5%), n-propyl acetate (98%), MIBK (98%), toluene (99.5%), xylene (97%) and HPLC water used as a diluents.

B. Method of preparation of Sample

a) Preparation of Stock solution: 1 g of each solvent weighed accurately and calculated the concentration involved in the analysis shown in Table 1 used as a stock solution.

b) Dilution: – Stock solution was diluted to varying concentrations used for analysis, where varying volume (1ml, 3ml, 5ml) of stock has been taken in GC/HS (20 ml) vial and diluted with 10 ml water varying concentrations shown in Table 1. Water was used as a preferred solvent as a standard, because of its polarity and compatibility with all solvents.

c) Concentration of each solvents: Concentration of all solvents has been calculated as per the standard calculation procedure as shown in Table 1.

Transfer the above prepared diluted three base concentration into GC-HS vials (20 ml) sealed and crimped. Each of the vials contains 10-50 ppm of methanol, 10-50 ppm of ethanol, 10-50 ppm of IPA, 10-50 ppm of n-propyl alcohol and 10-50ppm of other solvents with respect to the sample. The vials have 10ml water containing solvents at different concentrations; the vials are kept at 60°C injector temperature in headspace since a sufficient flow must be maintained through the system to avoid excessive peak broadening.

In this study, a HS-GC analytical method was developed and validated for the quantitative determination of the all the solvents methanol, ethanol, IPA, MEK, MIBK, EA, n-butanol, n-propyl acetate and so on. The proposed method uses the standard addition technique with internal standard quantization for determination of eleven solvents. The method was validated as per food safety regulation defined quantitation, linearity, range, precision (system repeatability), recovery and robustness (changes in HS and GC conditions and solution stability) were determined.

Excellent results were obtained, within global validation reference values, particularly taking into account the low concentration levels investigated. The test method was validated and had good Repeatability [Table 2], relative standard deviation RSD and linearity (%) [Table 3 and 4] and linearity [Figure 01, 02 and 03 and Table 4] for the solvents used for the current study.

The recovery was good and justified the preparation of the standard in water without the product as matrix. The linear range and correlation coefficients were determined between 10-50 ppm of each solvent.

The concentration of residual solvents (ppm) determined using the formula for solvent (Equation 1).

The ELITE-5 column, in the 30 m x 0.32 mm I.D. configuration, was chosen because this column has a standard stationary phase, which is recommended by the European and American Pharmacopeias, and has provided baseline of all solvents used in the validation, including the diluent (water). The method showed good peak shape, and the narrow peak width resulted in excellent column efficiency. The blank chromatogram did not show any interference with the solvent peaks.

To carry out this study, three concentrations were prepared for each solvent. All concentrations were prepared in triplicate, by individually weighing of solvents. The experimental results were represented graphically to obtain a calibration curve and carry out the corresponding statistical study (Anova). The method is linear within a wide range for the solvents included in the validation.

The correlation coefficients were all above 0.99 and linear regression showed a positive response throughout the range [Figure 2 and 3; Table 4]. The specified range is normally derived from linearity studies and depends on the intended application of the procedure[6]. In this paper it was characterized as the interval between the lowest (8 ppm) and highest (50 ppm) concentration, which can be determined using a given method, with assumed precision, trueness and linearity. This method determine lowest concentration so it is valid for wide measurement range allows determination with adequate precision of different solvents at higher concentration too. The measurement ranges are shown in the Table 4 with the respective RSD values.

LODs were calculated at S/N ratio of ≥ 3 and LOQs were calculated as at S/N ratio ≥10 and low-residual linearity values. The sensitivity of the method was demonstrated by the low-LOD values and low LOQ obtained for all the solvents analyzed.

The mean recoveries for all the solvents were between 95.0–105.3% and were lower than tabulated [Table 4], so the recoveries and 100% values were not significantly different.

The analytical method proposed for the quality control of all selected solvents methanol, ethanol, iso propyl alcohol, MEK, MIBK, n propyl alcohol, EA, n-butanol, n propyl acetate, toluene and xylene very well complete the validation requirements and precisely fit for various polarity solvents as the method was sensitive, linear, accurate and precise. Excellent results were obtained, within globally accepted validation reference values, particularly taking into account the low concentration levels investigated. 

The authors are thankful to Uflex Chemical Division for providing infrastructure and constructive criticism which have helped to accomplish this work.

1. Y. Sitaramaraju, A. Riadi, W. Autry, K. Wolfs, J. Hoogmartens, A.V. Schepdael and E. Adams, “Static headspace gas chromatography of (semi-) volatile drugs in pharmaceuticals for topical use,” J. Pharm. Biomed. Anal., 48, 2008, 113.

2. E.M. Antolín, Y.B. Quinónez, V.G. Canavaciolo, E.R. Cruz, “Validation of an analytical method for quality control of residual solvents (n-hexane and acetone) in D-002: new active ingredient from beeswax,” J. Pharm. Biomed. Anal. 47, 2008, 646.

3. Proceedings of International Conference on Harmonization of Technical Requirements for “Impurities: Residual Solvents” Registration of Pharmaceuticals for Human Use (ICH), Tripartite harmonized guideline 3C 1997.

4. P. Mahesh, K.Swapnalee, M. Aruna, B. Anilchandra, S. Prashanti, “Analytical Method Development And Validation of Acetaminophen, Caffeine, Phenylephrine Hydrochloride and Dextromethorphan Hydrobromide in Tablet Dosage Form By RP- HPLC,” Int. J. of Pharma., 2, 2013, 2319.

5. Y. Liu, and C.O. Hua,, “Establishment of a knowledge base for identification of residual solvents in pharmaceuticals,” Anal Chem. Acta,575, 2006, 246.

6. P. Mahesh, K. Swapnalee, M. Aruna, B. Anilchandra, S. Prashanti, “Analytical Method Development And Validation Of Acetaminophen, Caffeine ,Phenylephrine v Hydrochloride And Dextromethorphan Hydrobromide In Tablet Dosage Form By RP- HPLC,” Int J. of Pharmaceutical,2, 2013, 2319 – 6718.

Pallavi Gupta, masters in instrumentation, is currently working with Uflex Limited, Noida as chemist (R&D instrumentation). She has research experience of more than two years with the expertise in the area of analysis of and cross-verification quality checks of inks, adhesives, coatings, and multi components coatings by using state-of-the-art instruments like Py- GC-MS, GC-HS, FTIR, UV-spectrophotometer, HPLC, LCMS.

Dr. Ruchi Gupta, masters in industrial chemistry and Ph.D. in chemistry, is currently with Uflex Limited, Noida as manager (R&D), and prior to this, worked as a scientist with Shriram Institute for Industrial Research.

She has research experience of more than 11 years and her areas of interest include inks, adhesives, coatings, nanomaterials, nanophotocatalysts, optical polymers, natural polymers etc. She has published 12 papers in reputed international journals and has published four chapters in national and international handbooks.

Dr. Pinaki Ranjan Samanta has more than two decades of experience in the areas associated to industrial research of coating and testing of FG and RM’s of coating-related materials. He received M. Sc and Ph. D in the field of organic chemistry, also earning his PG diploma in paint technology.

He has published more than 12 papers in national and international journals, and also two patents in his cap in the field of high performance coatings. Since the middle of 1990s, he is an accomplished analytical chemist with years of research. Dr. Pinaki is experienced in the use of several analytical techniques including mass spectrometry (GC-MS, LC-MS), atomic spectrometry (AAS) and chromatography, and is also involved in the project development and research on new technology. Dr. Pinaki’s background includes tenures at reputed organizations like Berger Paints, Shriram Institute for Industrial Research, Moser Baer and Uflex in the area of research and development.

Pradeep Shah is a science graduate and has done B. Tech. chemical technology specialization in paints from Harcourt Butler Technological Institute Kanpur – 1980 batch. He has been selected from the campus by INCOWAX Ltd., now Flint Group India Ltd. He has done post- graduate diploma in business management (PGDBM).

He joined Uflex Group Chemical Division for its ink project in 1991 to start its ink plant with initial capacity of 3,000 tons per annum in Noida. The current capacity is 25,284 ton per annum with two plants located at Noida and Jammu in India. His total experience is more than 37 years.

Source link

Sichuan Kelun Pharmaceutical Automates Oncology Clinical Trial Set Up and Management with Clinical One Randomization and Supplies Management Cloud Service, Business News

CHENGDU, China, May 14, 2018 /PRNewswire/ — Oracle Health Sciences today announced that Sichuan Kelun Pharmaceutical Research Institute Co., Ltd (“Kelun”) has implemented Oracle Health Sciences Clinical One Randomization and Supplies Management Cloud Service to fully automate the set up and management of its multi-site, double blind colorectal cancer study. 

The China Food and Drug Administration (CFDA) has been driving reforms to improve the quality of drugs and to encourage innovation in the development of new drugs and medical devices. Kelun Pharmaceutical has been successfully conducting generics drug research since 1996 but recently launched its first, new oncology drug study. As with any new clinical trial, there is tremendous time and resources required to set up a new study including trial design and validation which can take weeks to months. ORS enables coordinators to quickly add patients to a trial, collect screening information and ensure eligibility for randomization in record time. In an effort to set up their own trial and eliminate manual, repetitive data entry, Kelun implemented Clinical One Randomization and Supplies Management Cloud Service.  

“We needed an established, standards-based cloud system to simplify the drug supply management process, and we have already determined we made a great choice by selecting Oracle’s Clinical One Randomization and Supplies Management. Within 29 days, we were fully implemented and are now in phase III of our oncology trial,” said Xiaoping Zhang, VP of Biostatistics and Data Management, Clinical Research Hub.

With Clinical One Randomization and Supplies Management, Kelun has been able to manage its trial supply and randomization more effectively and efficiently and has enabled its CRO partner and service providers, including its supply shipping specialist vendor, to automate their processes by leveraging Oracle Health Science’s cloud-based system. In addition to simplifying the drug supply management process, ORS has provided Kelun with role-based analytics to track and manage supply status in real time.

“Our eClinical platform, Clinical One and randomization and supplies management capability was designed for pharmaceutical and biopharma companies of all sizes, across all treatment areas and for all phases of research and development. We are excited to see Kelun leveraging technology to speed the setup and management of their trial and are hopeful that this oncology therapy will make it to market,” said Steve Rosenberg, general manager and senior vice president, Oracle Health Sciences.

Additional Resources

About Oracle
The Oracle Cloud offers complete SaaS application suites for ERP, HCM and CX, plus best-in-class database Platform as a Service (PaaS) and Infrastructure as a Service (IaaS) from data centers throughout the Americas, Europe and Asia. For more information about Oracle (NYSE:ORCL), please visit us at oracle.com

Trademarks
Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

Logo- https://ift.tt/2mPV2Zb

news POST

Purchase this article for republication.

Source link